A Review of Topical Imiquimod in the Management of Basal Cell Carcinoma, Actinic Keratoses, and Other Skin Lesions
作者： Jubin Ryu , F. Clarissa Yang
DOI: 10.4137/CMT.S1969
关键词:
摘要: Imiquimod (trade name Aldara™) is a small molecule of the imidazoquinoline family, group nucleoside analogs that were first synthesized as potential antiviral agents. It has since been discovered to activate both innate and adaptive immunity, well apoptosis. Clinically, it approved for three indications thus far: external genital warts, actinic keratosis, superficial basal cell carcinoma. In addition these applications, number off-label uses have reported in literature. this review, we summarize discuss literature describing imiquimod’s mechanism action, its clinical uses, safety tolerability.
sagepub.com
la-press.com参考文章(98)
V. W. Li, R. A. Ball, N. Vasan, W. W. Li, Antiangiogenic therapy for squamous cell carcinoma using combinatorial agents Journal of Clinical Oncology. ,vol. 23, pp. 3032- 3032 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.3032
Myriam Perrotta, Roberto Testa, Graciela Secco, Romina Pesce, Leonor Lugones, Claudia Marchitelli, Treatment of bowenoid and basaloid vulvar intraepithelial neoplasia 2/3 with imiquimod 5% cream. Journal of Reproductive Medicine. ,vol. 49, pp. 876- 882 ,(2004)
Ruslan Medzhitov, Paula Preston-Hurlburt, Charles A. Janeway, A human homologue of the Drosophila Toll protein signals activation of adaptive immunity Nature. ,vol. 388, pp. 394- 397 ,(1997) , 10.1038/41131
Renata L. A. Bottrel, Yi-Li Yang, David E. Levy, Mark Tomai, Luiz F. L. Reis, The Immune Response Modifier Imiquimod Requires STAT-1 for induction of Interferon, Interferon-Stimulated Genes, and Interleukin-6 Antimicrobial Agents and Chemotherapy. ,vol. 43, pp. 856- 861 ,(1999) , 10.1128/AAC.43.4.856
Thomas Ruzicka, Ronald G. J. Frank, Ullrich Munzel, Mosaad Megahed, Harald Gollnick, Carlos Guillen Barona, Joachim Maus, Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe European Journal of Dermatology. ,vol. 18, pp. 677- 682 ,(2008) , 10.1684/EJD.2008.0519
Helmut Schöfer, Arndt Van Ophoven, Tamara Lenz, Angelika Eul, Ulrike Henke, Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts European Journal of Dermatology. ,vol. 16, pp. 642- 648 ,(2006) , 10.1684/EJD.2006.0013
Michael J. Reiter, Traci L. Tester man, Richard L. Miller, Charles E. Weeks, Mark A. Tomai, Cytokine induction in mice by the immunomodulator imiquimod Journal of Leukocyte Biology. ,vol. 55, pp. 234- 240 ,(1994) , 10.1002/JLB.55.2.234
LesterI. Harrison, ShariL. Skinner, ThomasC. Marbury, MaryL. Owens, Sarala Kurup, Scott McKane, RobertJ. Greene, Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms Archives of Dermatological Research. ,vol. 296, pp. 6- 11 ,(2004) , 10.1007/S00403-004-0465-4
A. Alomar, J. Bichel, S. McRae, Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. British Journal of Dermatology. ,vol. 157, pp. 133- 141 ,(2007) , 10.1111/J.1365-2133.2007.07942.X
Carl Hashimoto, Kathy L. Hudson, Kathryn V. Anderson, THE TOLL GENE OF DROSOPHILA, REQUIRED FOR DORSAL-VENTRAL EMBRYONIC POLARITY, APPEARS TO ENCODE A TRANSMEMBRANE PROTEIN Cell. ,vol. 52, pp. 269- 279 ,(1988) , 10.1016/0092-8674(88)90516-8